Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30614296 | 1.00 | USP2 (0.55) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL7222368 | 0.84 | HDAC1 (0.54) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL1252105 | 0.83 | TYR (0.55) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL31241635 | 0.83 | TYR (0.55) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL8666600 | 0.83 | HDAC1 (0.55) | USP2GAAALOX15RAD51NPSR1 | |
| Ethoxycarbonyl Group SCHEMBL28291607 | 0.82 | CYP2A6 (0.43) | USP2GAAALOX15RAD51NPSR1 | |
| Tert-Butyl Formate SCHEMBL28290005 | 0.82 | CYP2A6 (0.43) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL14832829 | 0.81 | HDAC1 (0.58) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL9913530 | 0.79 | NPC1 (0.44) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL5057022 | 0.79 | AHR (0.50) | USP2GAAALOX15RAD51NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108828110-B | Method for determining residual quantity of benzimidazole drugs in chicken fat | 广东出入境检验检疫局检验检疫技术中心 | 2021-09-21 | — | — | CN | claimed |
| CN-109001334-B | Method for measuring residual quantity of benzimidazole drugs in chicken tissues | 广东出入境检验检疫局检验检疫技术中心 | 2021-04-27 | — | — | CN | claimed |
| WO-2002080906-A1 | PREVENTION AND TREATMENT OF ENDOMETRIOSIS WITH ARYL HYDROCARBON RECEPTOR BINDING LIGANDS | CEDARS-SINAI MEDICAL CENTER (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020147155-A1 | Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands | CEDARS-SINAI MEDICAL CENTER | 2002-10-10 | — | — | US | claimed |
| CN-111251500-B | Foaming polymer particles with skin dilatancy and preparation method thereof | 厦门天策材料科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118359656-A | Copper-catalyzed stannization reaction method for carbon-oxygen bond cleavage of aryl methanol | 天津师范大学 | 2024-07-19 | — | — | CN | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-111253583-B | Dilatant hybrid dynamic polymer and dilatant realization method thereof | 厦门天策材料科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-113754631-B | Heteroaryl method of indole | 中国科学院理化技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| EP-0442820-B1 | Benzimidazole and azabenzimidazole derivatives, thromboxane receptor antagonists, processes for their preparation, synthesis intermediates, compositions containing them | UNION PHARMA SCIENT APPL (FR) | 1995-09-13 | — | — | EP | disclosed |
| EP-0450345-B1 | Indole derivatives | MERCK PATENT GMBH (DE) | 1995-05-24 | — | — | EP | disclosed |
| US-5227386-A | INDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-07-13 | — | — | US | disclosed |
| EP-0450345-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1991-10-09 | — | — | EP | disclosed |
| EP-0442820-A1 | Benzimidazole and azabenzimidazole derivatives, thromboxane receptor antagonists, processes for their preparation, synthesis intermediates, compositions containing them | LABORATOIRES UPSA (FR) | 1991-08-21 | — | — | EP | disclosed |
| EP-0197294-B1 | BETA-LACTAM ANTIBIOTICS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1991-04-03 | — | — | EP | disclosed |
| US-4734407-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
| EP-0197294-A2 | Beta-lactam antibiotics, process for their preparation and their use as medicaments | BAYER AG (DE) | 1986-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | USP2 2615/4885GAA 810/4885ALOX15 3293/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | USP2 2615/4885GAA 810/4885ALOX15 3293/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | USP2 2615/4885GAA 810/4885ALOX15 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.